NCT07487844
Pulsed Electric Field Ablation for Metastatic Breast Cancer
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
At risk: Primary completion moved at least 4 months later.
See at-risk trials from University of California, San Francisco
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Primary and study completion pushed from Aug 1, 2028 to Dec 31, 2028
- Site contact updated
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 20 words
- Start date changed from estimate of Aug 15, 2026 to Jun 29, 2026
- Secondary endpoints: details revised at 3 of 3 entries
- Site details revised
- Notable Start date: May 15, 2026 to Aug 15, 2026
- Primary and study completion pushed from Jul 1, 2028 to Aug 1, 2028
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of participants with treatment-emergent adverse events
Timeframe: Up to 4 weeks
Secondary (3)
Mean change of score on European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Breast Cancer Module (EORTC QLQ BR-23)
Mean change of score on EuroQol five-dimensional Questionnaire (EQ-5D)
Mean technical success rate of Pulsed Electric Field (PEF) ablation
Arms and interventions
Image-Guided Pulsed Electric Field (PEF) AblationExperimental
Participants undergo a single treatment of PEF ablation delivered to up to 3 soft tissue metastatic breast cancer lesion(s). Ablation parameters, immediate adverse events, and post-ablation imaging will be collected during the ablation treatment.
Devices: Pulsed Electric Field (PEF) System
Behavioral: Questionnaires
Procedures: Tumor Ablation
Sites
1 site in 1 country
- University of California San FranciscoSan Francisco, California, United States